Skip to main content
Premium Trial:

Request an Annual Quote

Evident Technologies Forms Quantum Dot Collaboration with NIST

NEW YORK, Aug. 24 (GenomeWeb News) - Evident Technologies said today that it has entered into a cooperative research and development agreement with the National Institute of Standards and Technology to investigate the use of quantum dot composite fluorescent standards for biotech instrumentation.

 

"A fluorescence standard is necessary, especially for clinical applications, where quantification is required," Clint Ballinger, CEO, of Evident, said in a statement. "It is nearly impossible to quantify the fluorescence from an assay today, but our collaboration with NIST should greatly advance the state of the art."

 

Under the CRADA, Evident will provide quantum dot composites to NIST for characterization.

 

Additional terms were not disclosed.

 

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.